Skip to main content

neffy News

Many Kids Unnecessarily Hospitalized Following Allergic Reactions

FRIDAY, June 27, 2025 — Many kids are spending a lot of unnecessary time under observation in a hospital following a sudden allergic emergency, a new study concludes. About 17% of kids are admitted f...

ARS Pharmaceuticals Announces FDA Approval of neffy 1 mg (epinephrine nasal spray) for Type I Allergic Reactions in Pediatric Patients

SAN DIEGO, March 05, 2025 (GLOBE NEWSWIRE) – ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect...

ACAAI: Many Anaphylaxis Protocols Are Incomplete, Outdated

FRIDAY, Oct. 25, 2024 – Many anaphylaxis protocols are incomplete and/or outdated, and there is a need for patient education regarding treatment of anaphylaxis, according to two studies presented at...

Epinephrine: Tips to the 'EpiPen' Ingredient and How It Treats Anaphylaxis

TUESDAY, Oct. 8, 2024 --- The recent approval of a new epinephrine nasal spray, Neffy, gives patients a powerful new way to keep life-threatening allergic reactions at bay. But that doesn't mean...

FDA Approves neffy (epinephrine nasal spray) Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis

SAN DIEGO, Aug. 09, 2024 (GLOBE NEWSWIRE) – ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect patients...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Anaphylaxis, Allergic Reactions

neffy patient information at Drugs.com